POZ - Treatment News : Guidelines Reiterate Resistance Testing for All New HIV Cases
Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2008

Web Exclusives

AIDS Advocates Debate Obama's Policies

Evaluating the Costs of Earlier HIV Treatment

HIV Prevention Gets “Fergalicious”

» More

Most Talked About

Magic Johnson Accused of Faking HIV (42)

Guidelines Prediction: Start Treatment Earlier (blog) (19)

My First Facebook Demo (blog) (18)

World AIDS Day: Your Feedback (14)

Bone Marrow Transplant: Potential AIDS Cure? (9)

Obama Campaign Set to Boost Domestic HIV/AIDS Funding (8)

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Herpes Simplex Virus

Human Papilloma Virus (HPV)

Shingles

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

10 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailrssprint

July 3, 2008

Guidelines Reiterate Resistance Testing for All New HIV Cases

Drug-resistance testing is recommended at the time of HIV infection diagnosis, as well as in all cases of treatment failure, reiterate new guidelines from the International AIDS Society-USA (IAS-USA), published in the July 15 issue of Clinical Infectious Diseases.

The IAS-USA guidelines panelists, under the direction of Martin Hirsch, MD, of Harvard Medical School, stress the importance of testing to help HIV-positive people determine if they've been infected with a drug-resistant strain of HIV-and which drugs they're resistant to. For the most accurate results, they stress, testing should be conducted soon after the initial HIV diagnosis. Even if ARV treatment isn't to be started until several months or years later, the results of drug-resistance testing can help guide treatment decisions when the time comes.

Once patients are on ARV treatment, if viral load fails to go undetectable or becomes detectable again after a period of being undetectable, the 2008 IAS-USA recommendations restate that drug-resistance testing may help determine the cause. For best results, the test should be conducted while the failing regimen is being used, or within four weeks of discontinuing treatment.

The availability of new drugs from various classes and improvements in available assays necessitate updated guidelines to help people living with HIV and their health care providers make informed decisions when confronted with drug-resistant virus. The IAS-USA annually convenes a panel of physicians and scientists with expertise in drug-resistant HIV, ARV therapy and patient care to review recently published data and presentations at scientific conferences and to provide updated recommendations.

Search: drug resitance, drug resistance testing, genotype, phenotype, International AIDS Society, IAS-USA, Hirsch


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

         


[Go to top]


Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Would legalizing prostitution reduce the spread of HIV?
Yes
No
I don't know.

Monthly Poll
Question: Do you believe that prisoners receive adequate health care?
Yes
No
I don't know.

Surveys
Tell us about your overall health habits.

Tell us when and to whom you disclose your status.

more surveys
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy